Randomized Investigation of Heart Failure Therapy in Patients with Advanced Cancer at Risk of Cardiac Wasting: Rationale and Design of the EMPATICC Trial

EMPATICC evaluates whether HF therapy can improve function and well-being in advanced cancer, potentially reshaping care in this population.

Authors

Institutions

Publication Details

Journal
European Journal of Heart Failure
Published
2025-08-26
DOI
https://doi.org/10.1002/ejhf.3799
Citations
4
Primary Topic
Chemotherapy-induced cardiotoxicity and mitigation
Type
article
Field-Weighted Citation Impact
5.55

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Randomized Investigation of Heart Failure Therapy in Patients with Advanced Cancer at Risk of Cardiac Wasting: Rationale and Design of the EMPATICC Trial

Markus S. Anker, Lorenz Lehmann, Marius Placzek, Sven Bercker et al.
4 citations
European Journal of Heart Failure
Chemotherapy-induced cardiotoxicity and mitigation
5.55
article

Randomized Investigation of Heart Failure Therapy in Patients with Advanced Cancer at Risk of Cardiac Wasting: Rationale and Design of the EMPATICC Trial

Markus S. Anker, Lorenz Lehmann, Marius Placzek, Sven Bercker, Javed Butler, Johann Ahn, Ulrich Bernd Keller, Muhammad Shahzeb Khan, Martin Hellmich, Lars Bullinger, Raluca Mincu, Amir Abbas Mahabadi, Dominik Paul Modest, Tim Friede, Tienush Rassaf, Tim Heise, Monika Diek, Mitra Tewes, Ulf Landmesser, Matthias Totzeck, Michael Böhm, Stefan D. Anker, Bela Merkely
article en
4 citations

Abstract

EMPATICC evaluates whether HF therapy can improve function and well-being in advanced cancer, potentially reshaping care in this population.

European Journal of Heart FailureVol. 27(10)
Semmelweis University (HU), German Cancer Research Center (DE), Baylor College of Medicine (US), Max Delbrück Center (DE), Heidelberg University (DE), Temple College (US), University Hospital Heidelberg (DE), Jackson Memorial Hospital (US), University of Mississippi Medical Center (US), Humboldt-Universität zu Berlin (DE), Universitätsklinikum des Saarlandes (DE), Deutsches Herzzentrum der Charité (DE), Baylor Medical Center at Garland (US), National Center for Tumor Diseases (DE), Heart Hospital Baylor Plano (US), Universitätsmedizin Göttingen (DE), Essen University Hospital (DE), German Marine Research Consortium (DE), University Hospital Leipzig (DE), German Centre for Cardiovascular Research (DE), Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE), Klinik und Poliklinik für Neurologie (DE), Deutsches Herzzentrum München (DE), Berlin Heart (Germany) (DE), West German Heart and Vascular Center Essen (DE), Profil Institute for Metabolic Research (DE), Franklin University (US), University of Duisburg-Essen (DE), Charité - Universitätsmedizin Berlin (DE), University of Glasgow (GB)
European Society of Cardiology
Openalex Percentile: Top 4%
Chemotherapy-induced cardiotoxicity and mitigation
5.55
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.